R&D channel feed – Endpoints News

R&D channel feed

UK R&D credit increase, faster drug approvals promised in budget speech

3 years ago

FDA partially lifts dosing hold on Stoke Therapeutics' pediatric Dravet syndrome study

3 years ago

German cannabis medicine manufacturer lands $17M+ in funding

3 years ago

Dermavant says Vtama topical cream works in PhIII eczema trial

3 years ago

Sigilon focuses on type 1 diabetes, reduces spend on MPS-1 after letting CMO go (corrected)

3 years ago

Bellicum halts trials after serious adverse event, looks for 'strategic alternatives'

3 years ago

Further shuffling at Leo Pharma as dermatology drugmaker splits R&D

3 years ago

Servier says its next IDH inhibitor has passed PhIII, but no regulatory timeline yet

3 years ago

Synaffix expands ADC deal from 2022 with MacroGenics

3 years ago

Bristol Myers passes on two Exscientia oncology candidates, but biotech to move them into clinic next year

3 years ago

Exercise in a pill? That's the focus of Cambrian's new pipeline company

3 years ago

Novo-backed startup touts a PhII win for atrial fibrillation program

3 years ago

Sun Pharma, Taro Pharmaceutical reach $75M settlement agreement in alleged price fixing scheme

3 years ago

Calliditas plans to file for full approval for rare kidney disease drug following PhIII data

3 years ago

Vertex heads to the clinic with a next-gen stem cell candidate for type 1 diabetes

3 years ago

Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline

3 years ago

AstraZeneca touts PhIII event-free survival win with Imfinzi

3 years ago

Fresh Tracks considers options to stay afloat and develop autoimmune candidates

3 years ago

Tagrisso reaches OS endpoint in PhIII EGFR-mutated lung cancer trial

3 years ago

Ten years later, Lilly's long-term Alzheimer's trial of solanezumab has definitively failed

3 years ago

ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies

3 years ago

An eye, 15 seconds and striking animation: How Horizon's thyroid eye disease campaign hit home with patients

3 years ago

With PhII fail, Redx Pharma scraps monotherapy biliary cancer development for lead program

3 years ago

Despite mid-stage plaque psoriasis win, J&J appears undecided on PhIII for partner's IL-23 drug

3 years ago

First page Previous page 93 94 959697 98 99 Next page Last page